Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
7287721
Reference Type
Journal Article
Title
In Vitro Recovery of Sufentanil, Midazolam, Propofol, and Methylprednisolone in Pediatric Cardiopulmonary Bypass Systems
Author(s)
van Saet, A; Zeilmaker-Roest, GA; van Hoeven, MPJ; Koch, BCP; van Rosmalen, J; Kinzig, M; Sörgel, F; Wildschut, ED; Stolker, RJ; Tibboel, D; Bogers, AJJC
Year
2020
Is Peer Reviewed?
Yes
Journal
Journal of Cardiothoracic and Vascular Anesthesia
ISSN:
1053-0770
EISSN:
1532-8422
Volume
34
Issue
4
Page Numbers
972-980
Language
English
PMID
31561985
DOI
10.1053/j.jvca.2019.08.029
Web of Science Id
WOS:000520947600021
Abstract
OBJECTIVES:
To evaluate in vitro drug recovery in cardiopulmonary bypass (CPB) systems used for pediatric cardiac surgery.
DESIGN:
Observational in vitro study.
SETTING:
Single-center university hospital.
PARTICIPANTS:
In vitro CPB systems used for pediatric cardiac surgery.
INTERVENTIONS:
Three full neonatal, infant, and pediatric CPB systems were primed according to hospital protocol and kept running for 6 hours. Midazolam, propofol, sufentanil, and methylprednisolone were added to the venous side of the systems in doses commonly used for induction of general anesthesia. Blood samples were taken from the postoxygenator side of the circuit immediately after injection of the drugs and after 2, 5, 7, 10, 30, 60, 180, and 300 minutes.
MEASUREMENTS AND MAIN RESULTS:
Linear mixed model analyses were performed to assess the relationship between log-transformed drug concentration (dependent variable) and type of CPB system and sample time point (independent variables). The mean percentage of drug recovery after 60 and 180 minutes compared with T1 was 41.7% (95% confidence interval [CI] 35.9-47.4) and 23.0% (95% CI 9.2-36.8) for sufentanil, 87.3% (95% CI 64.9-109.7) and 82.0% (95% CI 64.6-99.4) for midazolam, 41.3% (95% CI 15.5-67.2) and 25.0% (95% CI 4.7-45.3) for propofol, and 119.3% (95% CI 101.89-136.78) and 162.0% (95% CI 114.09-209.91) for methylprednisolone, respectively.
CONCLUSIONS:
The present in vitro experiment with neonatal, infant, and pediatric CPB systems shows a variable recovery of routinely used drugs with significant differences between drugs, but not between system categories (with the exception of propofol). The decreased recovery of mainly sufentanil and propofol could lead to suboptimal dosing of patients during cardiac surgery with CPB.
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity